ArticleBMC pulmonary medicine2026
Prediction of intravenous cyclophosphamide treatment efficacy in idiopathic inflammatory myopathies-associated interstitial lung disease patients: a nomogram based on radiomics and clinical factors.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIntravenous cyclophosphamide (IV-CYC) is a first-line treatment for idiopathic inflammatory myopathy (IIMs) complicated with interstitial lung disease (ILD) but has been hampered by a lack of targeted clinical trials and heterogeneous patient responses. Therefore, this study established an evaluation model for IV-CYC treatment response in IIMs-ILD patients by combining clinical characteristics and radiomics.
methodsRetrospectively included total of 62 IIMs-ILD patients were enrolled and categorized into two groups on the basis of treatment response: the Effective group (n = 18) and the Non-effective group (n = 44). Baseline clinical and imaging characteristics were analyzed, with no significant differences observed in demographic or clinical factors between the groups. Least absolute shrinkage and selection operator (LASSO) regression identified five key predictors of treatment response: ROl_Lobe2 infected rates, ROl_Segment1 infected rates, anti-MDA5 antibody, anti-Jo1 antibody, and IgA levels.
resultsA nomogram incorporating these factors was developed, with an area under the curve (AUC) of 0.876 (95% CI: 0.788-0.964), a sensitivity of 0.889 and a specificity of 0.790. The model's Youden's index was 0.639. The calibration curve indicated strong agreement between the predicted and actual outcomes. Decision curve analysis (DCA) and a clinical impact curve (CIC) confirmed the model's clinical utility, showing significant net benefits in predicting the treatment response to IV-CYC in IIMs-ILD patients.
conclusionThe proposed nomogram provides a reliable tool for predicting treatment response in IIMs-ILD patients receiving IV-CYC therapy, potentially guiding personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.